ES2180538T3 - Suministro dirigido de vector virico a celulas de mamiferos. - Google Patents

Suministro dirigido de vector virico a celulas de mamiferos.

Info

Publication number
ES2180538T3
ES2180538T3 ES92922980T ES92922980T ES2180538T3 ES 2180538 T3 ES2180538 T3 ES 2180538T3 ES 92922980 T ES92922980 T ES 92922980T ES 92922980 T ES92922980 T ES 92922980T ES 2180538 T3 ES2180538 T3 ES 2180538T3
Authority
ES
Spain
Prior art keywords
pct
virus
direct supply
vector
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922980T
Other languages
English (en)
Inventor
Leif Lindholm
Sven Enerback
Orjan Strannegard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Got-A-Gene AB
Original Assignee
Got-A-Gene AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20384166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180538(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Got-A-Gene AB filed Critical Got-A-Gene AB
Application granted granted Critical
Publication of ES2180538T3 publication Critical patent/ES2180538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBE UN COMPLEJO ENTRE EL RECEPTOR DE ENLACE DE LA CELULA Y EL VIRUS QUE HA SIDO DESACTIVADO, Y UN ANTICUERPO, EL CUAL TIENE LA CAPACIDAD DE INTERACTUAR CON UN ANTIGENO ESPECIFICO SOBRE LA SUPERFICIE DE UNA CELULA DE MAMIFERO DISTINTA DE LA ESTRUCTURA CELULAR QUE DE OTRA MANERA INTERVIENE EN EL ENLACE DEL VIRUS CON LA SUPERFICIE DE LA CELULA, TENIENDO TAL ANTIGENO LA CAPACIDAD DE INTERVENIR EN LA ENTRADA DE UN VECTOR VIRUS O VIRUS INFECCIOSO DENTRO DE UNA CELULA DE MAMIFERO.
ES92922980T 1991-10-30 1992-10-28 Suministro dirigido de vector virico a celulas de mamiferos. Expired - Lifetime ES2180538T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller

Publications (1)

Publication Number Publication Date
ES2180538T3 true ES2180538T3 (es) 2003-02-16

Family

ID=20384166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922980T Expired - Lifetime ES2180538T3 (es) 1991-10-30 1992-10-28 Suministro dirigido de vector virico a celulas de mamiferos.

Country Status (9)

Country Link
US (1) US5695991A (es)
EP (1) EP0614486B1 (es)
JP (1) JPH07502026A (es)
AT (1) ATE224442T1 (es)
CA (1) CA2122613C (es)
DE (1) DE69232782T2 (es)
ES (1) ES2180538T3 (es)
SE (1) SE503225C2 (es)
WO (1) WO1993009221A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6261554B1 (en) 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
AU709831B2 (en) * 1995-11-13 1999-09-09 Takara Bio Inc. Method for gene transfer into target cells with retrovirus
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
WO1997038723A1 (en) * 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
WO1998047916A1 (en) * 1997-04-18 1998-10-29 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
CA2318981A1 (en) * 1998-02-09 1999-08-12 Genzyme Corporation Nucleic acid delivery vehicles
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US7078483B2 (en) * 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1372708B1 (en) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US11266736B2 (en) 2008-04-17 2022-03-08 Vin De Bona Trading Company Pte Ltd Method of painting micro vesicles
WO2009127537A1 (en) 2008-04-17 2009-10-22 GÜNZBURG, Walter Post release modification of viral envelopes
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (en) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
DE68927996T2 (de) * 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
EP1001032A3 (en) * 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
AU660629B2 (en) * 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller

Also Published As

Publication number Publication date
SE9103183D0 (sv) 1991-10-30
SE9103183L (sv) 1993-05-01
SE503225C2 (sv) 1996-04-22
CA2122613C (en) 2003-08-19
EP0614486B1 (en) 2002-09-18
EP0614486A1 (en) 1994-09-14
ATE224442T1 (de) 2002-10-15
WO1993009221A1 (en) 1993-05-13
US5695991A (en) 1997-12-09
JPH07502026A (ja) 1995-03-02
CA2122613A1 (en) 1993-05-13
DE69232782T2 (de) 2003-02-20
DE69232782D1 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
SE9103183D0 (sv) Virus-antibody complex
Maggi The mammalian tachykinin receptors
MY104946A (en) Antigen antibody conjugate.
NO913890L (no) Brenselcelle.
DE69126668D1 (de) Mycobacterium als adjuvans für antigene
DE68913032D1 (de) Brennstoffüberführungssystem für Luftfahrzeug.
DE69109336D1 (de) Festoxidbrennstoffzelle.
DK0502979T3 (da) Responselementpræparater og -assays for beta-retinsyre
NO883981L (no) Fast katalysatorkomponent for olefinkopolymerisasjon og fremgangsmaate for olefinkopolymerisasjon ved anvendelse av nevnte faste katalysatorkomponent.
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
EP0956304A4 (en) SPECIFIC ANTIBODIES FOR DENDRITIC CELLS
DE3777969D1 (de) Brennstoffzellenrecyclingsystem.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
DE60017019D1 (de) Antikörper gegen Spaltprodukte von Vimentin
PT553667E (pt) Receptor do ldl soluvel sua producao e utilizacao
DK0547200T3 (da) Rekombinante antistoffer på overfladen af E. coli
ATE169680T1 (de) 6-o-methylguanin-dna-methyltransferase (mgmt) spezifische antikörper
JPS5596713A (en) Outline vibration mode piezo-vibrator
DK467888A (da) Fremgangsmaade til fiksering af et antigen eller antistof samt et protein paa en baerer, saaledes overtrukket baerer og dens anvendelse.
DK164094C (da) Let konstruktionselement, isaer til vogndoere
EP0581108A3 (en) Bispecific antibody that reacts with sialyl-lea antigen and CD3.
ATE93141T1 (de) Verwendung von s-adenosylmethionin als mittel gegen virale infektionen durch retroviren.
FR2657879B1 (fr) Plaque de culture cellulaire.
SE9102014D0 (sv) Foerfarande i samband med mammalieceller